|
|
 |
|
Viewing report
|
|
|
|
Immunotherapy in Allergic Rhinitis - Moving Away from Injections
Datamonitor, April 2006, Pages: 68
Allergic rhinitis affects between 15% and 20% of the population in the seven major markets. Currently available treatments focus on symptom relief; however, a significant number of allergic rhinitis patients with uncontrolled symptoms remain. Shorter, safer, and more convenient therapies currently in development may lead to a substantial market expansion.
Scope of this title:
- Detailed break-down of the prevalence of allergic rhinitis by country, severity and type of allergen
- Evaluation of current strategies for the treatment of this disease, including the current role of immunotherapy
- Analysis of future trends in immunotherapy
- Assessment of the potential for new immunotherapies
Highlights of this title:
The prevalence of allergic rhinitis in the seven major markets ranges from 7.9% (Spain) to 17.2% (France), but only about half of the affected population currently seek treatment.
Immunotherapy is dominated by a few regional players, constituting a small niche within the EUR 16 billion allergic rhinitis market.
Several small companies are developing immunotherapy products with likely competitive advantages over currently available products. The aim is to achieve shorter sublingual immunotherapy courses.
Reasons to order your copy:
- Identify the most lucrative targets for immunotherapeutic product development strategies in allergic rhinitis
- Detailed breakdown of the prevalence of allergic rhinitis according to country, severity and allergen
- Gain competitive advantages when positioning new immunotherapies for allergic rhinitis
Customers who bought this item also bought
Commercial and Pipeline Insight: Allergic Rhinitis
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
Allergic Rhinitis Opinion Leader Forum, 2002
Treatment Algorithms 2001: Allergic Rhinitis - Unlocking the Real Patient Potential
Strategic Perspectives: Allergic Rhinitis - Impact of a blockbuster going bust
Commercial and Stakeholder Perspectives: Allergic Rhinitis - Is There Life After Claritin?
Pipeline Insight: Asthma, Copd and Allergic Rhinitis - The Needs of Severe Patients Must be Addressed
Rigels Allergic Rhinitis Candidate - R112
Pipeline Insight: Asthma, COPD and Allergic Rhinitis - Weak Late Stage Pipeline Leaves Innovation to Phase I/II Candidates
Market Dynamics 2000: Allergic Rhinitis: Effects of Major Patent Expiries On An Expanding Market
Drugs of Tomorrow 2000: Allergic Rhinitis - New Drug Classes, Towards Total Disease Management
Pipeline Insight: Asthma/COPD/Allergic Rhinitis - As Patents Expire, Novel Combinations Inspire
|
|
|
|
